Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1806 | Sirolimus | 3 | 72 | 0.32 | 8965.0 | 12104.5 | 1273.3 | -0.495 | 0.823 | 0.741 | 3.249 | HCC1806 Rapamycin 0 3 72 |
| HCC1806 | Sirolimus | 3 | 72 | 0.0032 | 9333.0 | 12104.5 | 1273.3 | -2.49 | 0.846 | 0.771 | 3.249 | HCC1806 Rapamycin 0 3 72 |
| HCC1806 | Sirolimus | 3 | 72 | 0.001 | 9616.0 | 12104.5 | 1273.3 | -3.0 | 0.863 | 0.794 | 3.249 | HCC1806 Rapamycin 0 3 72 |
| HCC1806 | Sirolimus | 3 | 72 | 0.1 | 9292.5 | 12104.5 | 1273.3 | -1.0 | 0.844 | 0.768 | 3.249 | HCC1806 Rapamycin 0 3 72 |
| HCC1806 | Sirolimus | 3 | 72 | 0.01 | 9275.5 | 12104.5 | 1273.3 | -2.0 | 0.843 | 0.766 | 3.249 | HCC1806 Rapamycin 0 3 72 |
| HCC1806 | Sirolimus | 3 | 72 | 0.032 | 9181.8 | 12104.5 | 1273.3 | -1.49 | 0.837 | 0.759 | 3.249 | HCC1806 Rapamycin 0 3 72 |
| HCC1806 | Sirolimus | 3 | 72 | 1.0 | 9238.3 | 12104.5 | 1273.3 | 0.0 | 0.840 | 0.763 | 3.249 | HCC1806 Rapamycin 0 3 72 |
| HCC1806 | Sirolimus | 3 | 72 | 3.2 | 8674.0 | 12104.5 | 1273.3 | 0.505 | 0.805 | 0.717 | 3.249 | HCC1806 Rapamycin 0 3 72 |
| HCC1806 | WYE-125132 | 3 | 72 | 0.32 | 5594.8 | 12050.8 | 1273.3 | -0.495 | 0.579 | 0.464 | 3.242 | HCC1806 WYE125132 0 3 72 |
| HCC1806 | WYE-125132 | 3 | 72 | 0.0032 | 11072.0 | 12050.8 | 1273.3 | -2.49 | 0.948 | 0.919 | 3.242 | HCC1806 WYE125132 0 3 72 |
| HCC1806 | WYE-125132 | 3 | 72 | 0.001 | 11365.0 | 12050.8 | 1273.3 | -3.0 | 0.964 | 0.943 | 3.242 | HCC1806 WYE125132 0 3 72 |
| HCC1806 | WYE-125132 | 3 | 72 | 1.0 | 5290.0 | 12050.8 | 1273.3 | 0.0 | 0.552 | 0.439 | 3.242 | HCC1806 WYE125132 0 3 72 |
| HCC1806 | WYE-125132 | 3 | 72 | 0.032 | 8601.3 | 12050.8 | 1273.3 | -1.49 | 0.802 | 0.714 | 3.242 | HCC1806 WYE125132 0 3 72 |
| HCC1806 | WYE-125132 | 3 | 72 | 3.2 | 5062.8 | 12050.8 | 1273.3 | 0.505 | 0.531 | 0.420 | 3.242 | HCC1806 WYE125132 0 3 72 |
| HCC1806 | WYE-125132 | 3 | 72 | 0.1 | 6801.8 | 12050.8 | 1273.3 | -1.0 | 0.677 | 0.564 | 3.242 | HCC1806 WYE125132 0 3 72 |
| HCC1806 | WYE-125132 | 3 | 72 | 0.01 | 10352.8 | 12050.8 | 1273.3 | -2.0 | 0.908 | 0.859 | 3.242 | HCC1806 WYE125132 0 3 72 |
| HCC1806 | Everolimus | 3 | 72 | 0.1 | 9054.3 | 12020.5 | 1273.3 | -1.0 | 0.832 | 0.753 | 3.239 | HCC1806 Everolimus 0 3 72 |
| HCC1806 | Everolimus | 3 | 72 | 0.032 | 9329.3 | 12020.5 | 1273.3 | -1.49 | 0.849 | 0.776 | 3.239 | HCC1806 Everolimus 0 3 72 |
| HCC1806 | Everolimus | 3 | 72 | 0.32 | 9042.0 | 12020.5 | 1273.3 | -0.495 | 0.832 | 0.752 | 3.239 | HCC1806 Everolimus 0 3 72 |
| HCC1806 | Everolimus | 3 | 72 | 0.001 | 10053.0 | 12020.5 | 1273.3 | -3.0 | 0.893 | 0.836 | 3.239 | HCC1806 Everolimus 0 3 72 |
| HCC1806 | Everolimus | 3 | 72 | 0.0032 | 9348.8 | 12020.5 | 1273.3 | -2.49 | 0.851 | 0.778 | 3.239 | HCC1806 Everolimus 0 3 72 |
| HCC1806 | Everolimus | 3 | 72 | 1.0 | 8742.8 | 12020.5 | 1273.3 | 0.0 | 0.813 | 0.727 | 3.239 | HCC1806 Everolimus 0 3 72 |
| HCC1806 | Everolimus | 3 | 72 | 3.2 | 8863.5 | 12020.5 | 1273.3 | 0.505 | 0.820 | 0.737 | 3.239 | HCC1806 Everolimus 0 3 72 |
| HCC1806 | Everolimus | 3 | 72 | 0.01 | 9417.5 | 12020.5 | 1273.3 | -2.0 | 0.855 | 0.783 | 3.239 | HCC1806 Everolimus 0 3 72 |
| HCC1806 | Pictilisib | 3 | 72 | 0.32 | 11380.8 | 11984.0 | 1273.3 | -0.495 | 0.968 | 0.950 | 3.234 | HCC1806 GDC0941 0 3 72 |